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LETTERS TO THE EDITOR
Systemic Inflammation,
Cardiorespiratory
Fitness, and Quality of
Life in Patients with
Advanced Non-small
Cell Lung Cancer
To the Editor:
The considerable amount of inter-
est in identifying robust markers of
prognostic in advanced non-small cell
lung cancer (NSCLC) has led to the
inconsistent identification of more than
150 risk factors.1 Among the wide num-
ber of prognostic risk factors identified,
performance status (PS) and systemic
inflammation have been shown to be
associated with weight loss, reduced
quality of life (QOL), and poorer sur-
vival in advanced NSCLC.2 However,
such investigations have been limited by
the use of current PS scoring systems
which are subjective and the use of only
one inflammatory marker (C-reactive
protein, CRP) to assess systemic inflam-
mation. The investigation of objective
measures of physical functioning and
other generic and lung cancer-specific
markers of systemic inflammation may
provide a more discriminatory evalua-
tion of patient’s clinical status allowing
for more accurate prognostication. Ac-
cordingly, we conducted a pilot study to
examine the association between an ob-
jective measure of physical functioning
(cardiorespiratory fitness), QOL, mark-
ers of systemic inflammation, and estab-
lished predictors of prognosis (i.e., PS,
weight loss, lung function) among 42
patients with histologically confirmed
inoperable NSCLC and PS 70.3
Cardiorespiratory fitness (VO2peak)
was determined using a physician-super-
vised cardiopulmonary exercise test with
12-lead electrocardiogram monitoring
(Mac 5000, GE Healthcare).3 Systemic
inflammatory markers included intracellu-
lar adhesion molecule (ICAM-1), macro-
phage inflammatory protein-1, interleu-
kin-6 (IL-6), IL-8, monocyte chemotactic
protein-1, CRP, and tumor necrosis factor
(TNF-). All markers were measured
in plasma using an enzyme-linked im-
munosorbent assay kit (ELISA; R&D
Systems, International Inc., Minneapolis,
MN). CRP was assessed in plasma using a
radioimmunoassay kit (Alpha Diagnos-
tics, Inc., San Antonio, TX). QOL was
assessed using the functional assessment
of cancer therapy (FACT-L) scale de-
veloped for the measurement of QOL in
NSCLC patients. Fatigue was assessed
by the 13-item fatigue scale of the
FACT measurement system. Pulmonary
function was determined by body ple-
thysmograph (6200 Autobox; Sensor-
Medics, Yorba Linda, CA) according to
American Thoracic Society guidelines.
PS was assessed using the Karnofsky
scoring system.
The majority of patients had low
cardiorespiratory fitness and elevated
levels of systemic inflammation. Mean
cardiorespiratory fitness was 16.5  5.0
ml/kg/min, equivalent to 67% of that
predicted for age and gender healthy
controls whereas 88, 50, 55, and 69% of
NSCLC patients had elevated levels of
IL-6 (3.0, pg/ml), TNF- (6.0, pg/
ml), ICAM-1 (300 ng/ml), and CRP
(3.0 mg/l), respectively.
Weight loss at diagnosis was pos-
itively associated with macrophage in-
flammatory protein-1 (r  0.35, p 
0.033) and TNF- (r 0.44, p 0.008)
whereas VO2peak was negatively associ-
ated with monocyte chemotactic pro-
tein-1 (r  0.34, p  0.033) and IL-8
(r  0.37, p  0.024). Age, gender
(being female), and body mass index
were inversely associated with VO2peak
(ml/kg/min) (r  0.47, p  0.002;
0.45, p  0.024; r  0.35, p 
0.024, respectively). There were no sig-
nificant associations between VO2peak,
QOL and markers of systemic inflam-
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TABLE 1. Differences Between Study Outcomes Based on Cardiorespiratory
Fitness
VO2peak <18 ml/kg/min
(n  27)
VO2peak >18 ml/kg/min
(n  15) p
Clinical characteristics
Age (yr) 67  10 58  10 0.010
Female (%) 33 5 0.014
BMI (kg/m2) 27  5 24  3 0.076
Weight loss at
diagnosis (%)
25 22 0.110
KPS 83  10 87  8 0.193
Hemoglobin (g/l) 13.7  1.7 14.8  1.5 0.039
FEV1 (liters) 1.9  0.6 2.4  .08 0.022
Cardiorespiratory fitness
data
VO2peak (ml/kg/min) 13.4  2.3 22.1  3.2 0.001
Systemic inflammation
data
ICAM-1 (ng/ml) 335.1  81.4 287.9  100.0 0.119
MIP-1  (pg/ml) 17.2  8.8 18.0  9.9 0.806
IL-6 (pg/ml) 14.5  12.4 12.0  9.7 0.542
IL-8 (pg/ml) 31.4  17.4 18.3  11.9 0.024
MCP-1 (pg/ml) 273.5  96.9 193.9  58.8 0.010
TNF- (pg/ml) 16.8  24.2 22.2  23.6 0.534
CRP (mg/l) 9.2  8.1 8.1  6.6 0.662
Quality of life data
FACT-L, 0–136 98.3  15.6 95.8  17.4 0.686
Fatigue, 0–52 18.1  12.0 13.5  8.6 0.236
Data presented as mean  SD.
BMI, body mass index; KPS, Karnofsky performance status; FEV1, forced expiratory volume in 1 second; VO2peak,
cardiorespiratory fitness; ICAM-1, intracellular adhesion molecule; MIP-1 , macrophage inflammatory protein; IL-6,
interleukin-6; IL-8, interleukin-8; MCP-1, monocyte chemotactic protein; CRP, c-reactive protein; TNF-, tumor
necrosis factor.
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mation. Differences between study out-
comes based on participant’s VO2peak
(18 ml/kg/min versus18 ml/kg/min)
is presented in Table 1. In general,
higher cardiorespiratory fitness was as-
sociated with more favorable clinic pro-
file, lower systemic inflammation, and
reduced fatigue.
The present results confirm that
lung carcinogenesis is associated with el-
evated levels of systemic inflammatory
markers such as TNF-, adhesion mole-
cules (ICAM-1), and acute phase pro-
teins—CRP and IL-6. This is of clinical
importance because these markers have
been shown to play pivotal roles in lung
carcinogenesis and in the pathogenesis of
related disorders such as cancer-related
anorexia and cachexia syndrome.4,5 The
prognostic value of these markers is not
currently known. Elevated levels of sev-
eral systemic inflammatory markers were
also associated with weight loss, higher
fatigue, and lower VO2peak. Of note, even
though PS was 70 for all participants,
VO2peak was, on average, 33% below age-
sex predicted norms. This is the first report
of low aerobic capacity using cardiopul-
monary exercise test, which is considered
the standard procedure assessment of car-
diorespiratory fitness. Low VO2peak has
been recognized as a strong, independent
predictor of cardiovascular mortality and
all-cause mortality in both diseased and
healthy populations. Higher VO2peak was
associated with more favorable clinic pro-
file, lower systemic inflammation, and re-
duced fatigue. As such, low VO2peak may
have significant implications for outcome
and management of NSCLC and studies
further exploring the utility of objective
measures of physical functioning appear
warranted.
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Factors Contributing to
Adjuvant Therapy
Decisions
To the Editor:
With recent randomized trials
showing an absolute survival benefit at
5 years of 8 to 15% with adjuvant
chemotherapy after complete resection
of early stage non–small-cell lung can-
cer (NSCLC),1,2 there has been rapid
uptake of adjuvant therapy as a new
standard in NSCLC in the oncology
community. But despite a significant
increase in prescribing practices of on-
cologists,3,4 as many as 50% of pa-
tients still decline potentially curative
adjuvant chemotherapy for lung can-
cer, in contrast to the high uptake of
adjuvant therapy by patients with breast
and colorectal cancer for a smaller ab-
solute survival benefit.
That lung cancer patients tend to be
older, have more comorbid illnesses,
lower socioeconomic status, and are pre-
dominantly male may all impact on this
difference. Platinum-based treatment may
be perceived as more toxic, and older lung
cancer patients are less willing to accept
even low levels of treatment-related tox-
icity.5 But are there additional barriers to
accepting adjuvant chemotherapy for pa-
tients with resected NSCLC?
Understanding elements of the pa-
tient decision-making process may iden-
tify barriers responsible for treatment re-
fusal that, once removed, could lead to
improved health outcomes for this patient
population. To elicit factors contributing
to patient decision-making regarding ad-
juvant therapy, we conducted semistruc-
tured interviews with patients following
resection of early stage NSCLC, including
those who had declined treatment.
Patients were most likely to use
their medical oncologist and surgeon as
information resources during the decision-
making process, with family members and
family practitioners also playing an impor-
tant role. Those who declined treatment
reported greater reliance on family as an
information resource, and used a narrower
spectrum of resources (e.g., brochures,
hospital classes, news magazines), com-
pared with those who accepted treatment.
Also, prior experience with chemotherapy
differed between the groups. Those who
declined treatment had less experience
with chemotherapy through friends and
family, but reported negative experiences.
Those who declined therapy were primar-
ily concerned with the potential for severe
consequences (e.g., prolonged duration of
feeling unwell, loss of independence, and
poor quality of life in remaining years of
advanced age). Those who accepted che-
motherapy were more likely to have had
exposure to chemotherapy experiences
through friends and family, but did not
report negative experiences.
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